An anti-cataract intravitreal implant has completed non-clinical testing, with an Australian phase 1/2 clinical study now underway.
US-based biopharmaceutical firm Nacuity’s new implant contains a small antioxidant molecule, NPI-002, designed to slow cataract progression. The study will enroll 30 patients undergoing vitrectomy and is expected to be completed in September 2022.
New research links glucosamine, a joint pain supplement, to a 25% higher likelihood of progression from mild cognitive impairment (MCI) to
Clinician-scientists identified bacterial pathogens linked to poorest outcomes in postprocedural acute endophthalmitis, potentially supporting faster, personalised treatment and improving patient
EssilorLuxottica and US company Applied Materials have joined forces to accelerate the commercialisation of next-generation intelligent optical systems for augmented reality and AI-powered smart eyewe…
Vanni Eyewear introduces model V1829, an oval frame with a unique nosepiece reinforcement that allows for thick lenses while maintaining lightness and thinness. Available in four colourways.
The Optometric Fees Negotiating Committee (OFNC) is seeking urgent feedback from General Ophthalmic Services (GOS) contractors in England regarding 2026/27 fees and grants, citing
EssilorLuxottica introduces Varilux Physio Extensee, the newest lens in the Varilux progressive lens family. Varilux Physio Extensee includes the Pupilizer technology which is derived from Essilor's AI Twinning technology and dynamic pupil modelling. The result is that wearers report +18% improvemen